Neal Walker - Mar 1, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: President and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-fact
Stock symbol: ACRS
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/3/2022, 05:04 PM
Previous filing: Feb 11, 2022
Next filing: Mar 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+96.2K	+7.76%		1.34M	Mar 1, 2022	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+18.3K	+1.37%		1.35M	Mar 1, 2022	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+18.3K	+1.35%		1.37M	Mar 2, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+336K		$0.00	336K	Mar 1, 2022	Common Stock	336K	$14.94	Direct	F2
transaction	ACRS	Restricted stock units	Award	$0	+96K		$0.00	96K	Mar 1, 2022	Common Stock	96K		Direct	F1, F3
transaction	ACRS	Restricted stock units	Options Exercise	$0	-96.2K	-50%	$0.00	96.2K	Mar 1, 2022	Common Stock	96.2K		Direct	F1, F4
transaction	ACRS	Restricted stock units	Options Exercise	$0	-18.3K	-25%	$0.00	54.8K	Mar 1, 2022	Common Stock	18.3K		Direct	F1, F5
transaction	ACRS	Restricted stock units	Options Exercise	$0	-18.3K	-33.33%	$0.00	36.5K	Mar 2, 2022	Common Stock	18.3K		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F3	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F4	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F5	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F6	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.